Literature DB >> 12399220

Impaired ketogenesis is a major mechanism for disturbed hepatic fatty acid metabolism in rats with long-term cholestasis and after relief of biliary obstruction.

Corinne Lang1, Simona Berardi, Markus Schäfer, Dolors Serra, Fausto G Hegardt, Lukas Krähenbühl, Stephan Krähenbühl.   

Abstract

BACKGROUND/AIMS: Rats with long-term cholestasis have reduced ketosis of unknown origin.
METHODS: Fatty acid metabolism was studied in starved rats with biliary obstruction for 4 weeks (bile duct ligated rats = BDL rats), and 3, 7, 14, 28 and 84 days after reversal of biliary obstruction by Roux-en-Y anastomosis (RY rats), and in sham-operated control rats.
RESULTS: BDL rats had reduced beta-hydroxybutyrate concentrations in plasma (0.25 +/- 0.10 vs. 0.75 +/- 0.20 mmol/l) and liver (2.57 +/- 0.20 vs. 4.63 +/- 0.61 micromol/g) which increased after restoring bile flow. Hepatic expression and activity of carnitine palmitoyltransferase I (CPT I) or CPT II were unaffected or decreased in BDL rats, respectively, and increased after restoring bile flow. Oxidative metabolism of different substrates by isolated liver mitochondria and activation of palmitate were reduced in BDL rats and recovered 7-14 days after restoring bile flow. Ketogenesis was decreased in mitochondria from BDL rats and recovered 3 months after restoring bile flow. Both mRNA and protein expression of hydroxymethylglutaryl-coenzyme A synthase (HMG-CoA synthase), the rate-limiting enzyme of ketogenesis, was reduced in livers of BDL rats and increased after reversing biliary obstruction.
CONCLUSIONS: In BDL rats, impairment of hepatic fatty acid metabolism is multifactorial. After reversing biliary obstruction, reduced activity of HMG-CoA synthase is the major factor. Copyright 2002 European Association for the Study of the Liver

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399220     DOI: 10.1016/s0168-8278(02)00248-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  5 in total

1.  Time course of acylcarnitine elevation in neonatal intrahepatic cholestasis caused by citrin deficiency.

Authors:  Ni-Chung Lee; Yin-Hsiu Chien; Keiko Kobayashi; Takeyori Saheki; Huey-Ling Chen; Pao-Chin Chiu; Yen-Hsuan Ni; Mei-Hwei Chang; Wuh-Liang Hwu
Journal:  J Inherit Metab Dis       Date:  2006-05-30       Impact factor: 4.982

2.  Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  Lauren N Bell; Jacob Wulff; Megan Comerford; Raj Vuppalanchi; Naga Chalasani
Journal:  Liver Int       Date:  2014-09-22       Impact factor: 5.828

3.  Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis.

Authors:  Yury Popov; Deanna Y Sverdlov; K Ramakrishnan Bhaskar; Anisha K Sharma; Gunda Millonig; Eleonora Patsenker; Stephan Krahenbuhl; Lukas Krahenbuhl; Detlef Schuppan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-01-07       Impact factor: 4.052

4.  Surgical treatment of 144 cases of hilar cholangiocarcinoma without liver-related mortality.

Authors:  Norihiko Furusawa; Akira Kobayashi; Takahide Yokoyama; Akira Shimizu; Hiroaki Motoyama; Sin-ichi Miyagawa
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

5.  Mitochondrial Mutations in Cholestatic Liver Disease with Biliary Atresia.

Authors:  Hong Koh; Gun-Seok Park; Sun-Mi Shin; Chang Eon Park; Seung Kim; Seok Joo Han; Huy Quang Pham; Jae-Ho Shin; Dong-Woo Lee
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.